#sequencingtechnology

Meticulous Research®, a leading global market research company, published a research report titled, 'Asia-Pacific NGS Automation Market by Product (Platform, Consumables), Sequencing Type (Whole Genome, Exome, Targeted), Application (Drug Discovery, Diagnostics), End User (Hospitals, Diagnostic Laboratories, Pharmaceutical, Academic) -  Forecast to 2032.'

According to this latest publication from Meticulous Research®, the Asia-Pacific NGS automation market is expected to reach $371 million by 2032, at a CAGR of 16.3% from 2025 to 2032.The growth of the Asia-Pacific NGS automation market is driven by the growing demand for NGS technology in clinical & research applications, the rising incidence of cancer, and increasing pharmaceutical R&D investments and healthcare expenditures. However, the high costs of automation workstations restrain the market's growth.

The increasing application of NGS in genetic disease testing and government initiatives aimed at boosting the adoption of advanced technologies are expected to create market growth opportunities. However, regulatory & standardization concerns related to diagnostic testing and the need to train personnel on the use of NGS automation software are major challenges for market growth.

Key Players

The key players operating in the Asia-Pacific NGS automation market are Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Eppendorf AG (Germany), Hamilton Company (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group Ltd. (Switzerland), PrimaDiag SAS (France), BRAND GMBH + CO KG (Germany), Hudson Robotics (U.S.), SPT Labtech (U.K.), Thermo Fisher Scientific, Inc. (U.S.), and F. Hoffmann-La Roche Ltd. (Switzerland).

Asia-Pacific NGS Automation Market: Future Outlook

The Asia-Pacific NGS automation market is segmented by Product (Workstations/Robotic Platforms and Reagents & Consumables), Sequencing Type (Whole Genome Sequencing (WGS), Whole Exome Sequencing, Targeted Genome Sequencing, and Other Sequencing Types), Application (Drug Discovery, Clinical Diagnostics [Reproductive Health Diagnostics, Oncology Diagnostics, Infectious Diseases Diagnostics, and Other Clinical Diagnostics], and Other Applications), End User (Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Other End Users), and Geography. The study also evaluates industry competitors and the market at the country level.

Among all products studied in this report, the workstations/robotic platforms segment is expected to register the highest CAGR during the forecast period. The growth of this segment is attributed to the increasing use of robotic platforms for liquid handling or pipetting to increase process efficiency, reduce manual errors, and reduce the time required. Additionally, increasing pharmaceutical R&D expenditure and rising applications of NGS in various fields are driving the market's growth.

Among all sequencing types studied in this report, in 2025, the whole genome sequencing segment is expected to account for the largest share of the Asia-Pacific NGS automation market. The large market share of this segment can be attributed to the increasing demand for whole genome sequencing for various applications, including the analysis of tumors, studying the causes and progression of diseases, selecting plants and animals for agricultural breeding programs, and examining common genetic variations among populations. Furthermore, whole genome sequencing facilitates the identification of known virulence factors and the derivation of comprehensive resistance profiles of pathogens against antibiotic drugs, further driving its adoption.

Among all applications studied in this report, the clinical diagnostics segment is expected to register the highest CAGR during the forecast period. The growth of this segment can be attributed to the growing utilization of NGS automation products in hospitals and diagnostic laboratories for preimplantation genetic testing, NIPT testing, carrier testing, and other applications. Additionally, factors such as the rising incidence of genetic disorders in infants, increasing awareness regarding genetic testing, and the introduction of advanced non-invasive prenatal testing (NIPT) products contribute to the growth of this segment. According to the Chinese Center for Disease Control and Prevention, the prevalence rate of congenital heart disease was 80.77 per 10,000 births between 2013 and 2022.

Among all end users studied in this report, in 2025, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the Asia-Pacific NGS automation market. The large market share of this segment can be attributed to the significant R&D investments made by pharmaceutical and biotechnology companies, coupled with the increasing incidence of chronic diseases, which drive the need for improved diagnostics and therapeutic approaches, thereby increasing the adoption of NGS technologies among pharmaceutical and biotechnology companies.

Geographic Review

This research report provides a comprehensive analysis of the market across major countries in the Asia-Pacific region, including Japan, China, India, South Korea, Australia, Thailand, Singapore, Indonesia, and the Rest of Asia-Pacific. China is expected to register the highest CAGR during the forecast period. This growth is driven by several factors, including the increasing government focus on sequencing projects, the establishment of new healthcare facilities, the large population of patients with gene-associated disorders, and the increasing research activities aimed at developing personalized medicines. Additionally, the increasing collaborations among government agencies and key players to expand genetic testing further support the market's growth in the country. For instance, the Newborn Foundation (U.S.), the Chinese Ministry of Health, and the National Office of Maternal and Child Health Services have collaborated for over a decade to conduct newborn screening for congenital heart defects and neonatal hypoxemia.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5790

Key questions answered in the report:

Which are the high-growth market segments in terms of the product, sequencing type, application, end user, and country?

What was the historical market for NGS automation products in Asia-Pacific?

What are the market forecasts and estimates for the period 2025–2032?

What are the major drivers, restraints, challenges, and opportunities in the Asia-Pacific NGS automation market?

Who are the major players in the Asia-Pacific NGS automation market?

Meticulous Research®, a leading global market research company, published a research report titled, 'Asia-Pacific NGS Automation Market by Product (Platform, Consumables), Sequencing Type (Whole Genome, Exome, Targeted), Application (Drug Discovery, Diagnostics), End User (Hospitals, Diagnostic Laboratories, Pharmaceutical, Academic) -  Forecast to 2032.'

According to this latest publication from Meticulous Research®, the Asia-Pacific NGS automation market is expected to reach $371 million by 2032, at a CAGR of 16.3% from 2025 to 2032.The growth of the Asia-Pacific NGS automation market is driven by the growing demand for NGS technology in clinical & research applications, the rising incidence of cancer, and increasing pharmaceutical R&D investments and healthcare expenditures. However, the high costs of automation workstations restrain the market's growth.

The increasing application of NGS in genetic disease testing and government initiatives aimed at boosting the adoption of advanced technologies are expected to create market growth opportunities. However, regulatory & standardization concerns related to diagnostic testing and the need to train personnel on the use of NGS automation software are major challenges for market growth.

Key Players

The key players operating in the Asia-Pacific NGS automation market are Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Eppendorf AG (Germany), Hamilton Company (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group Ltd. (Switzerland), PrimaDiag SAS (France), BRAND GMBH + CO KG (Germany), Hudson Robotics (U.S.), SPT Labtech (U.K.), Thermo Fisher Scientific, Inc. (U.S.), and F. Hoffmann-La Roche Ltd. (Switzerland).

Asia-Pacific NGS Automation Market: Future Outlook

The Asia-Pacific NGS automation market is segmented by Product (Workstations/Robotic Platforms and Reagents & Consumables), Sequencing Type (Whole Genome Sequencing (WGS), Whole Exome Sequencing, Targeted Genome Sequencing, and Other Sequencing Types), Application (Drug Discovery, Clinical Diagnostics [Reproductive Health Diagnostics, Oncology Diagnostics, Infectious Diseases Diagnostics, and Other Clinical Diagnostics], and Other Applications), End User (Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Other End Users), and Geography. The study also evaluates industry competitors and the market at the country level.

Among all products studied in this report, the workstations/robotic platforms segment is expected to register the highest CAGR during the forecast period. The growth of this segment is attributed to the increasing use of robotic platforms for liquid handling or pipetting to increase process efficiency, reduce manual errors, and reduce the time required. Additionally, increasing pharmaceutical R&D expenditure and rising applications of NGS in various fields are driving the market's growth.

Among all sequencing types studied in this report, in 2025, the whole genome sequencing segment is expected to account for the largest share of the Asia-Pacific NGS automation market. The large market share of this segment can be attributed to the increasing demand for whole genome sequencing for various applications, including the analysis of tumors, studying the causes and progression of diseases, selecting plants and animals for agricultural breeding programs, and examining common genetic variations among populations. Furthermore, whole genome sequencing facilitates the identification of known virulence factors and the derivation of comprehensive resistance profiles of pathogens against antibiotic drugs, further driving its adoption.

Among all applications studied in this report, the clinical diagnostics segment is expected to register the highest CAGR during the forecast period. The growth of this segment can be attributed to the growing utilization of NGS automation products in hospitals and diagnostic laboratories for preimplantation genetic testing, NIPT testing, carrier testing, and other applications. Additionally, factors such as the rising incidence of genetic disorders in infants, increasing awareness regarding genetic testing, and the introduction of advanced non-invasive prenatal testing (NIPT) products contribute to the growth of this segment. According to the Chinese Center for Disease Control and Prevention, the prevalence rate of congenital heart disease was 80.77 per 10,000 births between 2013 and 2022.

Among all end users studied in this report, in 2025, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the Asia-Pacific NGS automation market. The large market share of this segment can be attributed to the significant R&D investments made by pharmaceutical and biotechnology companies, coupled with the increasing incidence of chronic diseases, which drive the need for improved diagnostics and therapeutic approaches, thereby increasing the adoption of NGS technologies among pharmaceutical and biotechnology companies.

Geographic Review

This research report provides a comprehensive analysis of the market across major countries in the Asia-Pacific region, including Japan, China, India, South Korea, Australia, Thailand, Singapore, Indonesia, and the Rest of Asia-Pacific. China is expected to register the highest CAGR during the forecast period. This growth is driven by several factors, including the increasing government focus on sequencing projects, the establishment of new healthcare facilities, the large population of patients with gene-associated disorders, and the increasing research activities aimed at developing personalized medicines. Additionally, the increasing collaborations among government agencies and key players to expand genetic testing further support the market's growth in the country. For instance, the Newborn Foundation (U.S.), the Chinese Ministry of Health, and the National Office of Maternal and Child Health Services have collaborated for over a decade to conduct newborn screening for congenital heart defects and neonatal hypoxemia.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5790

Key questions answered in the report:

Which are the high-growth market segments in terms of the product, sequencing type, application, end user, and country?

What was the historical market for NGS automation products in Asia-Pacific?

What are the market forecasts and estimates for the period 2025–2032?

What are the major drivers, restraints, challenges, and opportunities in the Asia-Pacific NGS automation market?

Who are the major players in the Asia-Pacific NGS automation market?